Zobrazeno 1 - 10
of 88
pro vyhledávání: '"John A Tayek"'
Autor:
Stanislav Listopad, Christophe Magnan, Le Z Day, Aliya Asghar, Andrew Stolz, John A Tayek, Zhang-Xu Liu, Jon M Jacobs, Timothy R Morgan, Trina M Norden-Krichmar
Publikováno v:
PLOS Digital Health, Vol 3, Iss 2, p e0000447 (2024)
Distinguishing between alcohol-associated hepatitis (AH) and alcohol-associated cirrhosis (AC) remains a diagnostic challenge. In this study, we used machine learning with transcriptomics and proteomics data from liver tissue and peripheral mononucle
Externí odkaz:
https://doaj.org/article/70c69694d50b4a10aa033ee82af3e165
Publikováno v:
Clinical Nutrition Open Science, Vol 49, Iss , Pp 130-139 (2023)
Summary: Objective: To determine if calories delivered within the first 6-days of mechanical ventilation for ARDS improved 60-day mortality in patients with ARDS. Design and Setting: Retrospective evaluation of randomized open label, multicenter tria
Externí odkaz:
https://doaj.org/article/aa200de3b73a454282e75096cc6e15f5
Autor:
Andrew J. Buckler, Gheorghe Doros, April Kinninger, Suvasini Lakshmanan, Viet T. Le, Peter Libby, Heidi T. May, Joseph B. Muhlestein, John R. Nelson, Anna Nicolaou, Sion K. Roy, Kashif Shaikh, Chandana Shekar, John A. Tayek, Luke Zheng, Deepak L. Bhatt, Matthew J. Budoff
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
AimsResidual cardiovascular risk persists despite statin therapy. In REDUCE-IT, icosapent ethyl (IPE) reduced total events, but the mechanisms of benefit are not fully understood. EVAPORATE evaluated the effects of IPE on plaque characteristics by co
Externí odkaz:
https://doaj.org/article/e28ba1e2c20049cd892822ca733eba9c
Autor:
John A. Tayek, Andrew A. Stolz, Danh V. Nguyen, M. Wayne Fleischman, John A. Donovan, Joseph M. Alcorn, Daniel C-K. Chao, Aliya Asghar, Timothy R. Morgan, Divya Birudaraju, Greg Botwin, Hema Buddha, Lavanya Cherukuri, Sheena Cruz, Monique French, Rachel Gonzalez, Jessica Gozum, Rebecca Gutierrez, Sajad Hamal, Preston Head, Carol Jones, Neil Kaplowitz, Robert Lee, Lauren MacHarg, Susan Milstein, Yuxin Ouyang, Christy Rico, Cory Zarick
Publikováno v:
EClinicalMedicine, Vol 54, Iss , Pp 101689- (2022)
Summary: Background: In trials conducted in India, recombinant granulocyte colony stimulating factor (GCSF) improved survival in alcohol-associated hepatitis (AH). The aim of this trial was to determine the safety and efficacy of pegfilgrastim, a lon
Externí odkaz:
https://doaj.org/article/21ce9efa24d34c9a9784997ac1ab32fa
Autor:
Stanislav Listopad, Christophe Magnan, Aliya Asghar, Andrew Stolz, John A. Tayek, Zhang-Xu Liu, Timothy R. Morgan, Trina M. Norden-Krichmar
Publikováno v:
JHEP Reports, Vol 4, Iss 10, Pp 100560- (2022)
Background & Aims: Liver disease carries significant healthcare burden and frequently requires a combination of blood tests, imaging, and invasive liver biopsy to diagnose. Distinguishing between inflammatory liver diseases, which may have similar cl
Externí odkaz:
https://doaj.org/article/a8c226faa38c42908eda30464d20226b
Autor:
Josepmaria Argemi, Komal Kedia, Marina A. Gritsenko, Ana Clemente-Sanchez, Aliya Asghar, Jose M. Herranz, Zhang-Xu Liu, Stephen R. Atkinson, Richard D. Smith, Trina M. Norden-Krichmar, Le Z. Day, Andrew Stolz, John A. Tayek, Ramon Bataller, Timothy R. Morgan, Jon M. Jacobs
Publikováno v:
The American Journal of Pathology. 192:1658-1669
Alcohol-associated hepatitis (AH) is a form of liver failure with high short-term mortality. Recent studies have shown that defective function of hepatocyte nuclear factor 4 alpha (HNF4a) and systemic inflammation are major disease drivers of AH. Pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fe3b65b19b8fcbfb473c24435922b8c
https://doi.org/10.1016/j.ajpath.2022.08.009
https://doi.org/10.1016/j.ajpath.2022.08.009
Autor:
April Kinninger, Heidi T May, Chandana Shekar, Sion K. Roy, Suvasini Lakshmanan, Kashif Shaikh, Joseph B. Muhlestein, Deepak L. Bhatt, Viet T Le, John R Nelson, John A. Tayek, Matthew J. Budoff
Publikováno v:
European Heart Journal. 41:3925-3932
Aims Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains. Icosapent ethyl (IPE), a highly purified eicosapentaenoic acid ethyl ester, added
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f197147428df1f46efad821efc8cfb69
https://doi.org/10.1093/eurheartj/ehaa652
https://doi.org/10.1093/eurheartj/ehaa652
Autor:
Matthew J. Budoff, Viet T Le Pa, John R Nelson, Sion K. Roy, Heidi T May, Deepak L. Bhatt, John A. Tayek, April Kinninger, Joseph B. Muhlestein, Chandana Shekar, Suvasini Lakshmanan, Kashif Shaikh
Publikováno v:
Cardiovascular Research. 117:1070-1077
Aims Though statin therapy is known to slow coronary atherosclerosis progression and reduce cardiovascular (CV) events, significant CV risk still remains. In the REDUCE-IT study, icosapent ethyl (IPE) added to statin therapy reduced initial CV events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26faaa9ddb2ea20e93b2d681e6b03f84
https://doi.org/10.1093/cvr/cvaa184
https://doi.org/10.1093/cvr/cvaa184
Publikováno v:
Journal of intensive care medicine. 37(5)
Purpose To test the benefits of Solumedrol treatment in sepsis patients with a blunted adrenocorticotropic hormone (ACTH)-cortisol response (delta Results The mean age was 51 ± 2 (mean ± SEM) with 61% female. Groups were well matched with regard to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e37ba3244b4001aa3f5e1a0f25f6449
https://pubmed.ncbi.nlm.nih.gov/34516312
https://pubmed.ncbi.nlm.nih.gov/34516312
Autor:
Matthew J. Budoff, Suvasini Lakshmanan, John R Nelson, April Kinninger, John A. Tayek, Heidi T May, Joseph B. Muhlestein, Kashif Shaikh, Viet T Le, Chandana Shekar, Deepak L. Bhatt, Ilana Golub, Sion K. Roy, Andrew J. Buckler
Publikováno v:
Circulation. 142
Background: Residual cardiovascular (CV) risk persists despite statin therapy. In REDUCE-IT, icosapent ethyl (IPE) reduced total CV events by 30%, but the mechanisms of benefit are not fully understood. The EVAPORATE trial evaluated the effects of IP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3dbba7ec4a8a9a8497a0dbbcaa73e337
https://doi.org/10.1161/circ.142.suppl_3.15389
https://doi.org/10.1161/circ.142.suppl_3.15389